Assessment of the Diagnostic Potential of MiR-29a-3p and MiR-92a-3p As Circulatory Biomarkers in Acute Myeloid Leukemia

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2019 Dec 25

PMID 31870103

Citations 5

Authors

Marwa M Gado

Nahla O Mousa

M A Badawy

Maha A El Taweel

Ahmed Osman

Affiliations

Soon will be listed here.

Abstract

Background: Acute myeloid leukemia (AML) is a set of Myeloproliferative neoplasms that are identified by excessive growth of myeloid blasts and production of abnormal blood cells. AML is the most common type of acute leukemia that occurs in adults. In addition, AML progresses rapidly and is considered a fatal disease. Thus, there is an urgent need to find new targets for molecularly designed therapies. In This study, we evaluated the circulatory levels of microRNA-29a-3p (miR-29a-3p) and miR-92a-3p beside exploring the expression pattern of their target gene myeloid cell leukemia sequence1 (MCL1) to investigate the role of these molecules in AML pathophysiology and to assess their ability to diagnose AML patients.

Methods: 40 adult AML patients along with 20 healthy subjects were enrolled in this study. Plasma were separated from venous blood samples, collected on EDTA, of all individuals were used to assess circulating miRNAs' levels. In the meantime, total RNA was extracted from isolated leukocytes and was used to quantify target mRNA transcript levels.

Results: Our data revealed that the circulating levels of miR-29a-3p and miR-92a-3p exhibited significant reduction in 90% and 100% of AML patients, respectively, when compared to the control group (p<0.001). On the other hand, the transcript level of the target gene of these miRNAs, MCL1, showed a sharp increase in 77.5% (p<0.001) of AML patients, along with a negative correlation with its regulatory miRNAs, miR-29a-3p and miR-92a-3p.

Conclusion: Our data validates the negative regulatory role of miR-29a-3p and miR-92a-3p to the expression levels of MCL1 in peripheral blood and indicates that these miRNAs can be used as non-invasive diagnostic markers. Furthermore, our study highlights the therapeutic potential of miR-29a-3p and miR-92a-3p to target and downregulate a very important gene (MCL1), which is highly implicated in the pathogenesis of AML.

Citing Articles

lncRNA CRNDE Affects Th17/IL-17A and Inhibits Epithelial-Mesenchymal Transition in Lung Epithelial Cells Reducing Asthma Signs.

Yuan Y, He Y, Wasti B, Duan W, Jia J, Chen Z Oxid Med Cell Longev. 2023; 2023:2092184.

PMID: 36743692 PMC: 9897922. DOI: 10.1155/2023/2092184.

miR-29a-3p mitigates the development of osteosarcoma through modulating IGF1 mediated PI3k/Akt/FOXO3 pathway by activating autophagy.

Qi S, Xu L, Han Y, Chen H, Cheng A Cell Cycle. 2022; 21(18):1980-1995.

PMID: 35575588 PMC: 9415451. DOI: 10.1080/15384101.2022.2078614.

Identification of a prognostic signature based on copy number variations (CNVs) and CNV-modulated gene expression in acute myeloid leukemia.

Niu C, Wu D, Li A, Qin K, Hu D, Wang E Am J Transl Res. 2022; 13(12):13683-13696.

PMID: 35035707 PMC: 8748127.

Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma.

Elliott E, Hopkins L, Hensen R, Sutherland H, Haupt L, Griffiths L Front Genet. 2021; 12:768913.

PMID: 34899857 PMC: 8661906. DOI: 10.3389/fgene.2021.768913.

Long non‑coding RNA H19 regulates LASP1 expression in osteosarcoma by competitively binding to miR‑29a‑3p.

Jin H, Wang H, Jin X, Wang W Oncol Rep. 2021; 46(3).

PMID: 34328197 PMC: 8329914. DOI: 10.3892/or.2021.8158.

References

Zhang H, Luo X, Zhang P, Huang L, Zheng Y, Wu J . MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009; 4(11):e7826. PMC: 2773830. DOI: 10.1371/journal.pone.0007826. View

Liang D, Hou Y, Luo L, Ao L . Altered expression of miR-92a correlates with Th17 cell frequency in patients with primary biliary cirrhosis. Int J Mol Med. 2016; 38(1):131-8. PMC: 4899017. DOI: 10.3892/ijmm.2016.2610. View

Xu L, Xu Y, Jing Z, Wang X, Zha X, Zeng C . Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol. 2014; 3:17. PMC: 4086441. DOI: 10.1186/2162-3619-3-17. View

Barkley L, Santocanale C . MicroRNA-29a regulates the benzo[a]pyrene dihydrodiol epoxide-induced DNA damage response through Cdc7 kinase in lung cancer cells. Oncogenesis. 2013; 2:e57. PMC: 3740286. DOI: 10.1038/oncsis.2013.20. View

Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H . Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 2012; 139(2):223-9. PMC: 3549412. DOI: 10.1007/s00432-012-1315-y. View

Menzin J, Lang K, Earle C, Kerney D, Mallick R . The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002; 162(14):1597-603. DOI: 10.1001/archinte.162.14.1597. View

Xi Z, Wang P, Xue Y, Shang C, Liu X, Ma J . Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963. PMC: 5421901. DOI: 10.18632/oncotarget.15327. View

Kadia T, Kantarjian H, Konopleva M . Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. Oncotarget. 2019; 10(12):1250-1265. PMC: 6383813. DOI: 10.18632/oncotarget.26579. View

Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62. DOI: 10.1056/NEJM199909303411407. View

10.

Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y . Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 2010; 60(5):351-7. DOI: 10.1111/j.1440-1827.2010.02526.x. View

11.

Muluhngwi P, Krishna A, Vittitow S, Napier J, Richardson K, Ellis M . Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Cancer Lett. 2016; 388:230-238. PMC: 5318263. DOI: 10.1016/j.canlet.2016.12.007. View

12.

Choghaei E, Khamisipour G, Falahati M, Naeimi B, Mossahebi-Mohammadi M, Tahmasebi R . Knockdown of microRNA-29a Changes the Expression of Heat Shock Proteins in Breast Carcinoma MCF-7 Cells. Oncol Res. 2016; 23(1-2):69-78. PMC: 7842558. DOI: 10.3727/096504015X14478843952906. View

13.

Marcucci G, Mrozek K, Radmacher M, Garzon R, Bloomfield C . The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2010; 117(4):1121-9. PMC: 3056468. DOI: 10.1182/blood-2010-09-191312. View

14.

Trehoux S, Duchene B, Jonckheere N, Van Seuningen I . The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. Biochem Biophys Res Commun. 2014; 456(3):757-62. DOI: 10.1016/j.bbrc.2014.12.025. View

15.

Thomas L, Lam C, Edwards S . Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010; 584(14):2981-9. DOI: 10.1016/j.febslet.2010.05.061. View

16.

Pan R, Ruvolo V, Wei J, Konopleva M, Reed J, Pellecchia M . Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015; 126(3):363-72. PMC: 4504949. DOI: 10.1182/blood-2014-10-604975. View

17.

Wong L, Wang J, Liew O, Richards A, Chen Y . MicroRNA and Heart Failure. Int J Mol Sci. 2016; 17(4):502. PMC: 4848958. DOI: 10.3390/ijms17040502. View

18.

Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui R . Circulating MicroRNAs in Cancer: Potential and Challenge. Front Genet. 2019; 10:626. PMC: 6656856. DOI: 10.3389/fgene.2019.00626. View

19.

Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pelle E . Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol. 2018; 10:1758835918794630. PMC: 6116068. DOI: 10.1177/1758835918794630. View

20.

Lu L, Xue X, Lan J, Gao Y, Xiong Z, Zhang H . MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother. 2013; 68(1):13-9. DOI: 10.1016/j.biopha.2013.10.005. View